Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide-based immunotherapy in window-of-opportunity SCCHN
2024-513447-82-00Phase 2Completed
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Sep 2024
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of io102, IO103 + Montanide and PD-L1/IDO peptide vaccine in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Cliniques universitaires Saint-Luc. Started Sep 2024; status: completed.
02
Drugs
io102IO103 + MontanidePD-L1/IDO peptide vaccine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-513447-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513447-82-00.